Dr Richard Bogle PhD FRCP FESC FACC DHMSA
Consultant Cardiologist
  • Home
  • NHS Practice
    • NHS Practice
    • St Helier Hospital
    • Epsom Cardiac Day Unit
    • St George's Hospital Radial Lounge
    • Echocardiography
  • Biography
    • Qualifications
    • About me >
      • Curriculum vitae
    • Appraisal and Revalidation
    • BCIS Angioplasty Audit
    • Publications
    • Recent abstracts
    • Research
    • Charitable activity
  • The Heart
    • Cardiac Investigations >
      • AliveCor ECG monitor
      • Guide to investigations for suspected angina
      • CT calcium scoring
      • Electrocardiogram (ECG)
      • Exercise treadmill test
      • Echocardiogram
      • Valve disease
      • Coronary Angiography
      • Pressure Wire Studies
      • Intra-vascular Ultrasound
    • Arrhythmias >
      • Atrial fibrillation >
        • Stroke Risk in AF
        • New Oral Anticoagulants
        • Presentations on AF
      • Atrial flutter
      • Pre-excitation syndromes
      • Ventricular ectopic beats
      • Ventricular arrhythmias
      • Pacemaker
      • DC Cardioversion
    • Cardiomyopathy
    • Coronary heart disease >
      • Cardiac syndrome X
      • Coronary Angioplasty
      • Coronary bypass surgery
    • Dizziness and blackouts
    • Fitness to fly
    • Fitness to drive
    • Heart Failure
    • Hypertension >
      • Patients guide to blood pressure medication
      • Home blood pressure monitors
      • Hypertension diet
      • Laragh's method
      • Renal sympathetic ablation for hypertension
      • Conn's Syndrome
    • Heart Screening >
      • Sports Cardiology
      • Cardiovascular Disease Risk
    • Medications >
      • Glyceryl trinitrate
    • Patient information leaflets
  • News and Links
  • Miscellany
    • History of Medicine
    • History of Coronary Angiography and Angioplasty
    • Stamps in Cardiology
    • A History of Medicine in 100 Objects
    • BSE Acceditation Course Introduction
    • BSE Acceditation Course Physics
    • BSE Acceditation Course Anatomy and Function
    • BSE Acceditation Course Mitral
    • BSE Acceditation Course Aortic
    • BSE Acceditation Course Congenital
    • BSE Acceditation Course Pericardium
  • Blog
  • RACPC Form
  • Cardiology Teaching St Helier Hospital

Colchicine: More than just a treatment for gout?

27/1/2013

0 Comments

 
Picture
Colchicum autumnale
Colchicine from the autumn crocus (Colchicum autumnale) has been used in medicine for 2000 years. It is mentioned in the Ebers papyrus dating from ~1550BC and it was recognised as a treatment for gout in Dioscorides's De Materia Medica in the first century. Colchicine has shown beneficial effects in treatment of familial Mediterranean fever and recurrent pericarditis. More recent studies have investigated whether colchicine decreases atrial fibrillation after ablation and this week a new trial in JACC has shown that colchicine reduces cardiovascular events in patients with chronic stable angina.

In stable coornary artery disease a previous study showed that colchicine 0.5mg twice daily reduced CRP levels by 60%; interesting but hardly proof of a beneficial clinical effect. A clinical trial published in JACC this week has taken this one step forward and investigated the effects of colchicine in patients with stable angiographically proven coronary artery disease. The Low Dose Colchicine (LoDoCo) study investigated 532 patients randomized to open label colchicine (0.5mg per day) treatment or no colchicine for two years. After a 3 year median follow-up the primary outcome (acute coronary syndrome, out-of-hospital cardiac arrest, or noncardioembolic ischemic stroke) occurred in 16% of placebo versus 5.3% of colchicine treated patients (67% significant RRR; NNT 11). The primary endpoint was driven by the reduction in ACS events as you might expect. On the safety side there was an 11% drop out rate from the colchicine treated group due to adverse GI effects of the drug during the first 30 days of treatment. 

The mechanism of action of colchine in reducing ACS events is unclear and the authors postulate it is secondary to an anti-inflammatory effect reducing cytokines and certaining this trial provides some support for the paradigm that reducing inflammation is beneficial in ACS.  However we are still a long way from being able to conclude that colchicine is a therapy for stable CHD patients. A larger double blind clinical trial is needed before it could enter clinical practice for this indication.

But who would fund such a trial with with a drug that is generically available. This would seem like an ideal trial for an investigator led study funded from MRC/BHF or Wellcome. However it might just interest the Pharma and in this respect colchicine has history. In July 2009 the FDA officially announced that colchicine was effective in treating acute gout. But didn't we know that 1500 years ago! Well colchicine had never been officially approved by the FDA. Although the 1938 Food, Drug, and Cosmetic Act required new drugs be approved it allowed drugs already marketed to remain available. Colchicine was one of a number of drugs that the FDA never formally evaluated. In 2007 URL Pharma did studies with colchicine to investigate the drug's safety and efficacy in gout in a randomized controlled trial. On the basis of their results the FDA approved Colcrys (the URL brand of Colchicine) for treatment of acute gout. Because this was technically a new indication for the drug, the Hatch-Waxman Act authorized the FDA to give the company 3 years market exclusivity which led to the price of colchicine to rise 50-fold from 9 cents to $4.85 per tablet.  Ample enough reward considering the trial only had 185 participants with. A appropriately powered trial of colchinine in stable coronary disease would require a considerably greater number of participants and long period of follow-up so the rewards to Pharma might not be enough to make this viable. So colchicine remains an interesting drug and 2 millenia after its discovery we are still learning new things about its pharmacology but whether it will enter the cardiologists arena for treatment of coronary artery disease remains to be determined.

Low-Dose Colchicine for Secondary Prevention of Cardiovascular Disease. JACC 29 Jan 2013: Vol. 61, pp. 404-410.
Incentives for Drug Development — The Curious Case of Colchicine. N Engl J Med 2010;  362:2045-2047

0 Comments

    RSS Feed

    Picture

    Dr Richard Bogle

    The opinions expressed in this blog are strictly those of the author and should not be construed as the opinion or policy of my employers nor recommendations for your care or anyone else's. Always seek professional guidance instead.

    Archives

    November 2019
    March 2016
    February 2016
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    November 2013
    October 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013
    February 2013
    January 2013

    Categories

    All
    Ablation
    Acute Coronary Syndromes
    Acute Coronary Syndromes
    Adherence
    Angioplasty
    Anticoagulants
    Arrhythmia
    Association
    Atherosclerosis
    Atrial Fibrillation
    Auenbrugger
    Bergamot
    Brugada
    Calcium Channel Blockers
    Cancer
    Cardiovascular Risk
    Chest Pain
    Cholesterol
    Cleveland Street
    Clinical Examination
    Colchicine
    Compliance
    Concordance
    Congenital Heart Disease
    Coronary Artery Disease
    Coronary Artery Disease
    C-reactive Protein
    Decision Aids
    Diet
    Ectopics
    Eggs
    Ezetimibe
    Frailty
    Frank's Sign
    Guidelines
    Hawthorne Effect
    Heart Failure
    History Of Medicine
    Hypertension
    ICD
    Internet
    Interventional Cardiology
    Joseph Rogers
    Lipids
    Malaria
    Marathon
    Medicines
    Nice Guidelines
    Nitrovasodilators
    NOAC
    Nudge
    Nutrition
    OCT
    Palpitations
    Pharmacy
    Pressure Wire
    Proteus
    Salt
    Smoking
    Spironolactone
    Statins
    Statistics
    Stent
    Stress
    Stroke
    Syndrome X
    Takotsubo
    Valve-disease
    Vein Grafts
    Ventricular Ectopics
    VF/VT
    Warfarin
    Weekend Working
    Workhouse

    View my profile on LinkedIn
Return to home page

Privacy Statement
Disclaimer
© Dr Richard Bogle 2020
patient feedback
Photo used under Creative Commons from peddhapati